Nathaniel R Smilowitz1, Matthew C Weiss1, Rina Mauricio1, Asha M Mahajan1, Kaitlyn E Dugan1, Arvind Devanabanda1, Claudia Pulgarin2, Eugenia Gianos1, Binita Shah3, Steven P Sedlis3, Martha Radford1, Harmony R Reynolds4. 1. Cardiovascular Clinical Research Center, Leon H. Charney Division of Cardiology, Department of Medicine, New York University School of Medicine, New York, NY, USA. 2. Division of Clinical Research Informatics, New York University School of Medicine, New York, NY, USA. 3. Cardiovascular Clinical Research Center, Leon H. Charney Division of Cardiology, Department of Medicine, New York University School of Medicine, New York, NY, USA; Section of Cardiology, Department of Medicine, New York Harbor Health Care System, Veterans Affairs Hospital, New York, NY, USA. 4. Cardiovascular Clinical Research Center, Leon H. Charney Division of Cardiology, Department of Medicine, New York University School of Medicine, New York, NY, USA. Electronic address: harmony.reynolds@nyumc.org.
Abstract
BACKGROUND: Type 2 myocardial infarction (MI) is defined as myocardial necrosis (myonecrosis) due to an imbalance in supply and demand with clinical evidence of ischemia. Some clinical scenarios of supply-demand mismatch predispose to myonecrosis but limit the identification of symptoms and ECG changes referable to ischemia; therefore, the MI definition may not be met. Factors that predispose to type 2 MI and myonecrosis without definite MI, approaches to treatment, and outcomes remain poorly characterized. METHODS: Patients admitted to an academic medical center with an ICD-9 diagnosis of secondary myocardial ischemia or non-primary diagnosis of non-ST-elevation MI were retrospectively reviewed. Cases were classified as either MI (n=255) or myonecrosis without definite MI (n=220) based on reported symptoms, ischemic ECG changes, and new wall motion abnormalities. RESULTS: Conditions associated with type 2 MI or myonecrosis included non-cardiac surgery (38%), anemia or bleeding requiring transfusion (32%), sepsis (31%), tachyarrhythmia (23%), hypotension (22%), respiratory failure (23%), and severe hypertension (8%). Inpatient mortality was 5%, with no difference between patients with MI and those with myonecrosis (6% vs. 5%, p=0.41). At discharge, only 43% of patients received aspirin and statin therapy. CONCLUSIONS: Type 2 MI and myonecrosis occur frequently in the setting of supply-demand mismatch due to non-cardiac surgery, sepsis, or anemia. Myonecrosis without definite MI is associated with similar in-hospital mortality as type 2 MI; both groups warrant further workup for cardiovascular disease. Antiplatelet and statin prescriptions were infrequent at discharge, reflecting physician uncertainty about the role of secondary prevention in these patients.
BACKGROUND:Type 2 myocardial infarction (MI) is defined as myocardial necrosis (myonecrosis) due to an imbalance in supply and demand with clinical evidence of ischemia. Some clinical scenarios of supply-demand mismatch predispose to myonecrosis but limit the identification of symptoms and ECG changes referable to ischemia; therefore, the MI definition may not be met. Factors that predispose to type 2 MI and myonecrosis without definite MI, approaches to treatment, and outcomes remain poorly characterized. METHODS:Patients admitted to an academic medical center with an ICD-9 diagnosis of secondary myocardial ischemia or non-primary diagnosis of non-ST-elevation MI were retrospectively reviewed. Cases were classified as either MI (n=255) or myonecrosis without definite MI (n=220) based on reported symptoms, ischemic ECG changes, and new wall motion abnormalities. RESULTS: Conditions associated with type 2 MI or myonecrosis included non-cardiac surgery (38%), anemia or bleeding requiring transfusion (32%), sepsis (31%), tachyarrhythmia (23%), hypotension (22%), respiratory failure (23%), and severe hypertension (8%). Inpatient mortality was 5%, with no difference between patients with MI and those with myonecrosis (6% vs. 5%, p=0.41). At discharge, only 43% of patients received aspirin and statin therapy. CONCLUSIONS:Type 2 MI and myonecrosis occur frequently in the setting of supply-demand mismatch due to non-cardiac surgery, sepsis, or anemia. Myonecrosis without definite MI is associated with similar in-hospital mortality as type 2 MI; both groups warrant further workup for cardiovascular disease. Antiplatelet and statin prescriptions were infrequent at discharge, reflecting physician uncertainty about the role of secondary prevention in these patients.
Authors: Wendy Lim; Ismael Qushmaq; P J Devereaux; Diane Heels-Ansdell; François Lauzier; Afisi S Ismaila; Mark A Crowther; Deborah J Cook Journal: Arch Intern Med Date: 2006 Dec 11-25
Authors: Kristian Thygesen; Joseph S Alpert; Allan S Jaffe; Maarten L Simoons; Bernard R Chaitman; Harvey D White; Kristian Thygesen; Joseph S Alpert; Harvey D White; Allan S Jaffe; Hugo A Katus; Fred S Apple; Bertil Lindahl; David A Morrow; Bernard R Chaitman; Peter M Clemmensen; Per Johanson; Hanoch Hod; Richard Underwood; Jeroen J Bax; Jeroen J Bonow; Fausto Pinto; Raymond J Gibbons; Keith A Fox; Dan Atar; L Kristin Newby; Marcello Galvani; Christian W Hamm; Barry F Uretsky; Ph Gabriel Steg; William Wijns; Jean-Pierre Bassand; Phillippe Menasche; Jan Ravkilde; E Magnus Ohman; Elliott M Antman; Lars C Wallentin; Paul W Armstrong; Maarten L Simoons; James L Januzzi; Markku S Nieminen; Mihai Gheorghiade; Gerasimos Filippatos; Russell V Luepker; Stephen P Fortmann; Wayne D Rosamond; Dan Levy; David Wood; Sidney C Smith; Dayi Hu; Jose-Luis Lopez-Sendon; Rose Marie Robertson; Douglas Weaver; Michal Tendera; Alfred A Bove; Alexander N Parkhomenko; Elena J Vasilieva; Shanti Mendis; Jeroen J Bax; Helmut Baumgartner; Claudio Ceconi; Veronica Dean; Christi Deaton; Robert Fagard; Christian Funck-Brentano; David Hasdai; Arno Hoes; Paulus Kirchhof; Juhani Knuuti; Philippe Kolh; Theresa McDonagh; Cyril Moulin; Bogdan A Popescu; Zeljko Reiner; Udo Sechtem; Per Anton Sirnes; Michal Tendera; Adam Torbicki; Alec Vahanian; Stephan Windecker; Joao Morais; Carlos Aguiar; Wael Almahmeed; David O Arnar; Fabio Barili; Kenneth D Bloch; Ann F Bolger; Hans Erik Botker; Biykem Bozkurt; Raffaele Bugiardini; Christopher Cannon; James de Lemos; Franz R Eberli; Edgardo Escobar; Mark Hlatky; Stefan James; Karl B Kern; David J Moliterno; Christian Mueller; Aleksandar N Neskovic; Burkert Mathias Pieske; Steven P Schulman; Robert F Storey; Kathryn A Taubert; Pascal Vranckx; Daniel R Wagner Journal: J Am Coll Cardiol Date: 2012-09-05 Impact factor: 24.094
Authors: Tomasz Baron; Kristina Hambraeus; Johan Sundström; David Erlinge; Tomas Jernberg; Bertil Lindahl Journal: Heart Date: 2014-10-20 Impact factor: 5.994
Authors: Luciano Babuin; Vlad C Vasile; Jose A Rio Perez; Jorge R Alegria; High-Seng Chai; Bekele Afessa; Allan S Jaffe Journal: Crit Care Med Date: 2008-03 Impact factor: 7.598
Authors: David A Morrow; Stephen D Wiviott; Harvey D White; Jose C Nicolau; Ezio Bramucci; Sabina A Murphy; Marc P Bonaca; Christian T Ruff; Benjamin M Scirica; Carolyn H McCabe; Elliott M Antman; Eugene Braunwald Journal: Circulation Date: 2009-05-18 Impact factor: 29.690
Authors: David M Iser; Alexander J V Thompson; Koon Ket Sia; Neville D Yeomans; Robert Y M Chen Journal: J Gastroenterol Hepatol Date: 2007-06-07 Impact factor: 4.029
Authors: Heidi M Crane; Pathmaja Paramsothy; Daniel R Drozd; Robin M Nance; J A Chris Delaney; Susan R Heckbert; Matthew J Budoff; Greer A Burkholder; James H Willig; Michael J Mugavero; William C Mathews; Paul K Crane; Richard D Moore; Joseph J Eron; Sonia Napravnik; Peter W Hunt; Elvin Geng; Priscilla Hsue; Carla Rodriguez; Inga Peter; Greg S Barnes; Justin McReynolds; William B Lober; Kristina Crothers; Matthew J Feinstein; Carl Grunfeld; Michael S Saag; Mari M Kitahata Journal: JAMA Cardiol Date: 2017-03-01 Impact factor: 14.676
Authors: Xiongyi Han; Myung Ho Jeong; Liyan Bai; Joon Ho Ahn; Dae Young Hyun; Kyung Hoon Cho; Min Chul Kim; Doo Sun Sim; Young Joon Hong; Ju Han Kim; Youngkeun Ahn Journal: Cardiovasc Diagn Ther Date: 2022-02
Authors: Hanumantha R Jogu; Sameer Arora; Muthiah Vaduganathan; Arman Qamar; Ambarish Pandey; Parag A Chevli; Tusharkumar H Pansuriya; Muhammad I Ahmad; Abhishek Dutta; Padageshwar R Sunkara; Waqas Qureshi; Sujethra Vasu; Bharathi Upadhya; Deepak L Bhatt; James L Januzzi; David Herrington Journal: Clin Cardiol Date: 2019-04-12 Impact factor: 2.882
Authors: Xiongyi Han; Liyan Bai; Myung Ho Jeong; Joon Ho Ahn; Dae Young Hyun; Kyung Hoon Cho; Min Chul Kim; Doo Sun Sim; Young Joon Hong; Ju Han Kim; Youngkeun Ahn Journal: Yonsei Med J Date: 2021-05 Impact factor: 2.759
Authors: Sameer Arora; Paula D Strassle; Arman Qamar; Evan N Wheeler; Alexandra L Levine; Jacob A Misenheimer; Matthew A Cavender; George A Stouffer; Prashant Kaul Journal: J Am Heart Assoc Date: 2018-03-26 Impact factor: 5.501